{"schema_version":"secwatch.filing_event.v1","accession":"0001609550-24-000050","form_type":"8-K","ticker":"INSP","cik":"0001609550","company_name":"Inspire Medical Systems, Inc.","filed_at":"2024-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.957648+00:00","generated_at":"2026-05-30T06:06:23.936679+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Inspire Medical Q3 revenue $203.2M (+33% YoY), EPS $0.60 vs loss, raises FY guidance","bullets":["Revenue $203.2M, up 33% YoY; U.S. revenue $195.8M (+33%), OUS $7.4M (+27%).","Operating income $14.3M vs loss $13.5M; net income $18.5M, diluted EPS $0.60 vs loss $0.29.","Raises FY 2024 revenue guidance to $793-798M (27-28% growth) and EPS guidance to $1.20-1.40.","Activated 66 new U.S. centers (total 1,371); created 13 new sales territories (total 323).","Received FDA approval for Inspire V neurostimulation system; gross margin steady at 84.1%."],"urls":{"canonical":"https://secwatch.observer/filing/0001609550-24-000050","json":"https://secwatch.observer/filing/0001609550-24-000050.json","markdown":"https://secwatch.observer/filing/0001609550-24-000050.md","text":"https://secwatch.observer/filing/0001609550-24-000050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1609550/000160955024000050/0001609550-24-000050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1609550/000160955024000050/insp-20241104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T06:06:23.936679+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}